Background: Age-related macular degeneration is the leading cause of blindness, with an increasing incidence as the elderly population expands.
Objective: In this article we review current therapeutic strategies and discuss possible future targets.
Methods: A review of the literature and ongoing clinical trials was undertaken.
Results: Currently, established therapies for neovascular AMD-like photodynamic therapy and anti-VEGF therapies allow stabilization or even improvement of vision. Potential future drugs under development for advanced AMD or its prevention target the signal transduction cascade of different angiogenic molecules. These drugs intervene at different levels of the involved processes including the RNA production and specific protein expression as well as inflammatory, apoptotic, or metabolic processes.
Conclusion: Combining different strategies targeting angiogenesis, inflammation and apoptosis, or interfering early in--or even prior to--the formation of choroidal neovascularization, may improve the future management of age-related macular degeneration.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1517/14728210902824141 | DOI Listing |
Ophthalmologie
January 2025
Klinik für Augenheilkunde, Universitätsklinikum Ulm, Prittwitzstr. 43, 89075, Ulm, Deutschland.
Comprehensive multimodal imaging is essential for the precise clinical diagnostics of neovascular age-related macular degeneration (nAMD). Noninvasive optical coherence tomography (OCT) is of prime importance regarding the baseline examination, follow-up and monitoring during treatment. The OCT imaging in nAMD eyes enables a high-resolution assessment of the retinal micromorphology, which can be considerably disturbed in different layers.
View Article and Find Full Text PDFCell Death Dis
January 2025
Laboratory of Developmental Cell Biology and Disease, State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.
Epithelial-to-mesenchymal transition (EMT) is a critical and complex process involved in normal embryonic development, tissue regeneration, and tumor progression. It also contributes to retinal diseases, such as age-related macular degeneration (AMD) and proliferative vitreoretinopathy (PVR). Although absent in melanoma 2 (AIM2) has been linked to inflammatory disorders, autoimmune diseases, and cancers, its role in the EMT of the retinal pigment epithelium (RPE-EMT) and retinal diseases remains unclear.
View Article and Find Full Text PDFKlin Monbl Augenheilkd
January 2025
Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
PLoS One
January 2025
UCL Institute of Ophthalmology, University College London, London, United Kingdom.
The outer retina (OR) is highly energy demanding. Impaired energy metabolism combined with high demands are expected to cause energy insufficiencies that make the OR susceptible to complex blinding diseases such as age-related macular degeneration (AMD). Here, anatomical, physiological and quantitative molecular data were used to calculate the ATP expenditure of the main energy-consuming processes in three cell types of the OR for the night and two different periods during the day.
View Article and Find Full Text PDFNon-peptide ligands (NPLs), including lipids, amino acids, carbohydrates, and non-peptide neurotransmitters and hormones, play a critical role in ligand-receptor-mediated cell-cell communication, driving diverse physiological and pathological processes. To facilitate the study of NPL-dependent intercellular interactions, we introduce MetaLigand, an R-based and web-accessible tool designed to infer NPL production and predict NPL-receptor interactions using transcriptomic data. MetaLigand compiles data for 233 NPLs, including their biosynthetic enzymes, transporter genes, and receptor genes, through a combination of automated pipelines and manual curation from comprehensive databases.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!